Cephalexin (Xenara)
Cephalexin
Aurogen South Africa (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Aurogen South Africa (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Xenara oral suspension 125 mg/5 ML EACH 5,0 ml SUSPENSION CONTAINS: CEPHALEXIN MONOHYDRATE EQUIVALENT TO CEPHALEXIN 125,0 mg | 125 mg/5 mlOral suspension | 550158.15655/20.1.1/0158.156 | Cancelled | Not determined | None |
| Xenara oral suspension 250 mg/5 ML EACH 5,0 ml SUSPENSION CONTAINS: CEPHALEXIN MONOHYDRATE EQUIVALENT TO CEPHALEXIN 250,0 mg | 250 mg/5 mlOral suspension | 550159.15755/20.1.1/0159.157 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(6R,7R)-7-[[(2R)-2-Amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Drag to rotate. Structure from PubChem CID 27447.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.